Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 24/7/2017
SIETES contiene 91907 citas

 
 
 1 a 20 de 173 siguiente >>
Presentar resultados
Seleccionar todas
1.Tiene citas relacionadas Cita con resumen
Grosser T. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med 2017;376:1389-90. [Ref.ID 101526]
2.
Felson DT. Safety of nonsteroidal antiinflammatory drugs.. N Engl J Med 2016;373:2595-6. [Ref.ID 101348]
3.Tiene citas relacionadas Cita con resumen
Nissen SE, Yeomans ND, Solomon DH, Lüscher TF, Libby P, Husni ME, Graham DY, Borer JS, Wisniewski LM, Wolski KE, Wang Q, Menon V, Ruschitzka F, Gaffney M, Beckeman B, Berger MF, Bao W, Lincoff AM, for the PRECISION Trial Investigators. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med 2016;373:2519-29. [Ref.ID 101038]
4.Enlace a cita original
Adrion C, Fischer CS, Wagner J, Gürkov R, Mansmann U, Strupp M, on behalf of the BEMED study group. Efficacy and safety of betahistine treatment in patients with Meniere’s disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial). BMJ 2016;352:h6816. [Ref.ID 100188]
5.Enlace a cita original Cita con resumen
Hayward KL, Powell EE, Irvine KM, Martin JH. Can paracetamol (acetaminophen) be administered to patients with liver impairment?. Br J Clin Pharmacol 2016;81:210-22. [Ref.ID 100097]
6. Cita con resumen
Kibuuka H, Berkowitz NM, Millard M, Enama ME, Tindikahwa A, Sekiziyivu AB, Costner P, Sitar S, Glover D, Hu Z, Joshi G, Stanley D, Kunchai M, Eller LA, Bailer RT, Koup RA, Nabel GL, Mascola JR, Sullivan NJ, Graham BS, Roederer M, Michael NL, Robb ML, Ledgerwood JE, the RV 247 Study Team. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial. Lancet 2015;385:1545-54. [Ref.ID 99098]
8.Enlace a cita original
Anónimo. Skin-cancer drug Zelboraf (vemurafenib): new warning on the risk of pancreatitis.. Health Canada 2015:12 de febrero. [Ref.ID 98847]
9.Tiene citas relacionadas
Bangalore S, Toklu B, Amoroso N, Fusaro M, Kumar S, Hannan EL, Faxon DP, Feit F. Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis. BMJ 2013;347:f6625. [Ref.ID 97174]
10.Tiene citas relacionadas Cita con resumen
Navarese EP, Tandjung K, Claessen B, Andreotti F, Kowalewski M, Kandzari D, Kereiakes D, Waksman R, Mauri L, Meredith IT, Finn AV, Kim HS, Kubica J, Suryapranata H, Mustahsani T, Di Pasquale G, von Birgelen C, Kedhi E. Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis. BMJ 2013;347:f6530. [Ref.ID 97173]
11.Enlace a cita original
Valkhoff VE, Schade R, Jong GW, Romio S, Schuemie MJ, Arfe A, Garbe E, Herings R, Lucchi S, Picelli G, Schink T, Straatman H, Villa M, Kuipers EJ, Sturkenboom MCJM, and on behalf of the investigators of the safety of non-steroidal anti-inflammatory drugs (SOS) project. Population-based analysis of non-steroidal anti-inflammatory drug use among children in four European countries in the SOS project: what size of data platforms an which study designs do we need to assess safety issues?. BMC Pediatrics 2013;13:192. [Ref.ID 96743]
12. Cita con resumen
Anónimo. Pesticides et maladie de Parkinson. Prescrire 2013;33:943. [Ref.ID 96727]
13.Tiene citas relacionadas
Riley JL. Combination checkpoint blockade - Taking melanoma immunotherapy to the next level. N Engl J Med 2013;369:187-9. [Ref.ID 95821]
14.Tiene citas relacionadas
Hamid O, Robert C, Daud A, Hodi FS, Hwu W-J, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A. Safety and tumour responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:133-44. [Ref.ID 95817]
15.Tiene citas relacionadas
Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesckhin AM, Segal NH, Ariyan CE, Godon R-A, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-33. [Ref.ID 95816]
16. Cita con resumen
Trilla A. Seguridad y efectividad de la vacuna antigripal: nuevos datos, nuevos retos. Med Clin (Barc) 2013;141:67-9. [Ref.ID 95764]
17.Enlace a cita original
Egunsola O, Adefurin A, Fakis A, Jacqz-Aigrain E, Choonara I, Sammons H. Safety of fluconazole in paediatrics: a systematic review. Eur J Clin Pharmacol 2013;69:1211-21. [Ref.ID 95557]
18.Tiene citas relacionadas Cita con resumen
Eurich DT, Simpson S, Senthilselvan A, Asche CV, Sandhu-Minhas JK, McAlister FA. Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study. BMJ 2013;346:14. [Ref.ID 95532]
19.Tiene citas relacionadas Cita con resumen
Segal J. Should we be reassured about sitagliptin?. BMJ 2013;346:8. [Ref.ID 95528]
Seleccionar todas
 
 1 a 20 de 173 siguiente >>